2.38

3.03% 0.07

After Hours: 2.40 0.02 +0.84%

Cabaletta Bio Inc (CABA)

Overview News Price History Option Chain Financials Why CABA Down? Discussions Forecast

Cabaletta Bio Inc stock is traded at $2.38, with a volume of 1.82M. It is up +3.03% in the last 24 hours and up +5.31% over the past month. Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies, and exploring their potential to provide a deep and durable, perhaps curative, treatment, for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) has the potential to be applied across a broad range of autoimmune diseases.

Previous Close:

$2.31

Open:

$2.27

24h Volume:

1.82M

Relative Volume:

0.80

Market Cap:

$116.33M

Revenue:

Net Income/Loss:

$-67.68M

P/E Ratio:

-1.3757

EPS:

-1.73

Net Cash Flow:

$-54.24M

1W Performance:

-15.60%

1M Performance:

+5.31%

6M Performance:

-71.43%

1Y Performance:

-88.81%

1-Day Range:

$2.23

$2.51

1-Week Range:

$2.17

$2.80

52-Week Range:

$1.76

$26.35

Cabaletta Bio Inc Stock (CABA) Company Profile

Name

Cabaletta Bio Inc

Sector

Healthcare (1176)

Industry

Biotechnology (673)

Phone

(267) 759-3100

Address

2929 ARCH STREET, PHILADELPHIA, PA

Employee

154

Twitter

@CabalettaBio

Next Earnings Date

2024-11-07

Latest SEC Filings

CABA's Discussions on Twitter

Compare CABA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
CABA Cabaletta Bio Inc	2.38	116.33M	0	-67.68M	-54.24M	-1.66
VRTX Vertex Pharmaceuticals Inc	397.27	102.31B	10.63B	-479.80M	-1.35B	-1.99
REGN Regeneron Pharmaceuticals Inc	701.85	77.13B	13.85B	4.65B	3.32B	40.41
ARGX Argen X Se Adr	623.82	37.30B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	245.44	31.66B	2.09B	-332.26M	16.06M	-2.62
BNTX Biontech Se Adr	113.08	27.11B	3.30B	-501.07M	1.03B	-2.1146

Cabaletta Bio Inc Stock (CABA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Oct-10-24	Initiated	UBS	Buy
Feb-05-24	Initiated	Jefferies	Buy
Nov-29-23	Initiated	William Blair	Outperform
Oct-24-23	Initiated	Cantor Fitzgerald	Overweight
Oct-19-23	Initiated	Stifel	Buy
Sep-05-23	Initiated	Citigroup	Buy
Jul-18-23	Initiated	Guggenheim	Buy
Jan-27-23	Upgrade	Morgan Stanley	Equal-Weight → Overweight
Aug-30-22	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Dec-08-21	Initiated	Wells Fargo	Overweight
Oct-19-21	Resumed	Morgan Stanley	Overweight
Jun-30-21	Initiated	Mizuho	Buy
Jan-08-21	Initiated	Chardan Capital Markets	Buy
Oct-13-20	Initiated	H.C. Wainwright	Buy
Nov-19-19	Initiated	Cowen	Outperform
Nov-19-19	Initiated	Evercore ISI	Outperform
Nov-19-19	Initiated	Morgan Stanley	Overweight

View All

Cabaletta Bio Inc Stock (CABA) Latest News

Dec 20, 2024

Cabaletta Bio's SWOT analysis: autoimmune CAR-T stock faces challenges, opportunities By Investing.com - Investing.com South Africa

Dec 20, 2024

Cabaletta Bio's SWOT analysis: autoimmune CAR-T stock faces challenges, opportunities - Investing.com

Dec 20, 2024

Cabaletta Bio (NASDAQ:CABA) Lowered to "Inline" Rating by Evercore ISI - MarketBeat

Dec 20, 2024

Dec 19, 2024

Wells Fargo Downgrades Cabaletta Bio (CABA) - MSN

Dec 19, 2024

Charles Schwab Investment Management Inc. Raises Stake in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Dec 19, 2024

This C3.ai Analyst Turns Bearish; Here Are Top 5 Downgrades For Thursday - Benzinga

Dec 19, 2024

Cabaletta Bio (NASDAQ:CABA) Downgraded by Wells Fargo & Company to Equal Weight - MarketBeat

Dec 19, 2024

Dec 17, 2024

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Holdings in Cabaletta Bio, Inc. (NASDAQ:CABA) - Defense World

Dec 17, 2024

Dec 15, 2024

Cabaletta Bio's SWOT analysis: CAR-T pioneer's stock faces pivotal moment - Investing.com

Dec 15, 2024

Dec 10, 2024

Cabaletta Bio, Inc.'s (NASDAQ:CABA) latest 25% decline adds to one-year losses, institutional investors may consider drastic measures - Yahoo Finance

Dec 10, 2024

Is Cabaletta Bio (NASDAQ:CABA) In A Good Position To Invest In Growth? - Simply Wall St

Dec 10, 2024

Point72 Asset Management L.P. Makes New $3.15 Million Investment in Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Dec 10, 2024

Dec 06, 2024

Jennison Associates LLC Reduces Stake in Cabaletta Bio Inc - GuruFocus.com

Dec 06, 2024

PRUDENTIAL FINANCIAL INC's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com

Dec 06, 2024

Dec 05, 2024

Walleye Capital LLC Acquires 212,025 Shares of Cabaletta Bio, Inc. (NASDAQ:CABA) - MarketBeat

Dec 05, 2024

Dec 03, 2024

US Stocks Likely To Open In The Green To End November On A High: Are Markets Set For A Santa Claus Rally In December? Analysts Decode - Benzinga

Nov 29, 2024

Cabaletta Bio, Inc. (NASDAQ:CABA) Receives $27.30 Consensus PT from Analysts - MarketBeat

Nov 29, 2024

Nov 28, 2024

Caballeta Bio Shares Surge The Most In 23 Months In A Single Day As It Unveils Plan To Meet FDA By 2025 For Systemic Sclerosis Drug Trial - Benzinga

Nov 28, 2024

Nov 27, 2024

CABA Stock Earnings: Cabaletta Bio Misses EPS for Q1 2024 - MSN

Nov 27, 2024

Cabaletta Bio’s CAR-T CABA-201 Effects Clinical Responses in Autoimmune Diseases - CGTLive™

Nov 27, 2024

Nov 26, 2024

Cabaletta Bio to Participate in Upcoming Investor Conferences in December - The Manila Times

Nov 26, 2024

Nov 25, 2024

2 Penny Stocks That Wall Street Predicts Will Soar 306% To 1,183% In 2025 - Barchart

Nov 25, 2024

2 Penny Stocks That Wall Street Predicts Will Soar 306% to 1,183% in 2025 - Inkl

Nov 25, 2024